Granulomatosis with Polyangiitis (Wegener’s)

This presentation offers a comprehensive exploration of Granulomatosis with Polyangiitis (GPA)—a rare but potentially life-threatening ANCA-associated small- to medium-vessel vasculitis characterized by necrotizing granulomatous inflammation and systemic involvement. It reviews the epidemiology, genetic and environmental risk factors, and immunopathogenesis, with particular emphasis on PR3-ANCA–mediated neutrophil activation, granuloma formation, and vascular injury. Clinical features such as chronic sinusitis, pulmonary nodules, hematuria, glomerulonephritis, cutaneous lesions, and neurological manifestations are discussed in depth.

Diagnostic strategies include ANCA serology (c-ANCA/PR3), imaging, urinalysis, and histopathological confirmation of necrotizing granulomatous vasculitis. Conventional management relies on high-dose corticosteroids, immunosuppressive agents, and biologics targeting B-cells and complement pathways. Beyond these established therapies, the presentation introduces advanced regenerative and integrative innovations, including Precursor Stem Cell Therapy (PSCT), Autologous Active Specific Immunotherapy (AASI®), Nano Organo Peptides (NOP) Thymus and Mito Organelle (MO) Thymus for Thymus Therapy, Nano Organo Peptides (NOP) Super Transfer Factor (STF), Mito Organelles (MO) Super Transfer Factor (STF), and GcMAF Forte. Supported by clinical evidence and case-based insights, this program is tailored for rheumatologists, nephrologists, pulmonologists, and healthcare professionals seeking a deeper understanding of GPA and the next generation of therapeutic strategies.